Clinical Trials Directory

Trials / Unknown

UnknownNCT03505840

The Value of Placental Vascularization and Placental Volume in Pregnancy in APLS

TheValue of Placental Vascularization Indices and Placental Volume in Pregnancies With Antiphospholipid Syndrome for Prediction of Neonatal Outcome"

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Aljazeera Hospital · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

Antiphospholipid antibodies are autoantibodies directed against phospholipid-binding proteins. Among these groups of antibodies, lupus anticoagulant (LA) and anticardiolipin antibodies (aCL)

Detailed description

APLS can be primary when no evidence of autoimmune disease is found, or secondary to autoimmune processes like systemic lupus erythematous (SLE) in a 40% of the cases.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTUltrasound with Doppler and 3D technologyultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology

Timeline

Start date
2018-04-24
Primary completion
2020-09-04
Completion
2020-10-10
First posted
2018-04-23
Last updated
2020-01-27

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03505840. Inclusion in this directory is not an endorsement.

The Value of Placental Vascularization and Placental Volume in Pregnancy in APLS (NCT03505840) · Clinical Trials Directory